Ingrezza for Tardive Dyskinesia: Its Safety, Efficacy, and Implication

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

Laxman Bahroo, DO, director of the Botulinum Toxin Clinic and associate professor of Neurology at Georgetown University Hospital, took time out of the 21st International Congress of Parkinson's Disease and Movement Disorders to discuss Ingrezza, the first and only treatment approved for Tardive Dyskinesia.